Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astellas Pharma announces Mycamine approval

Astellas Pharma announces Mycamine approval

12th May 2008

Astellas Pharma has announced that its European subsidiary has been granted marketing approval from the European Medicines Agency for Mycamine (micafungin sodium).

The compound has been approved for use in Europe in a number of indications.

These include the treatment of invasive candidiasis, prophylaxis of Candida infection in patients undergoing allgeneic haematopoietic stem cell transplantation or those expected to have neutropenia for ten or more days.

Another approved indication is the treatment of oesophageal candidiasis in patients for whom intravenous therapy is suited .

The company announced plans to launch the compound in the UK before subsequently making the drug available across the European market.

“This approval in Europe means that Mycamine will be available in the US, Asia and Europe and Astellas is expecting that Mycamine will be a new option for the treatment of Candida infections throughout Europe,” the company said.

It added that it is dedicated to developing an infectious diseases franchise, with the growth of this franchise led by the approval of Mycamine in Europe.

Last month, Asetllas announced that it had signed an exclusive agreement with CoMentis for the development and marketing of products from that company’s beta-secretase inhibitor programme.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.